FDA pulls approval for avastin in breast cancer
- PMID: 22586694
- DOI: 10.1158/2159-8290.CD-ND112311OL-08
FDA pulls approval for avastin in breast cancer
Abstract
The FDA has revoked approval of the breast cancer indication for bevacizumab (Avastin; Genetech), saying that studies have not shown enough of a benefit to outweigh the drug's serious and potentially life-threatening side effects.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
